Mission Statement
To create a sustainable, fast-growing and profitable global speciality pharmaceutical business with a substantial franchise in the allergy sector by developing innovative, patented, registered therapies for both the treatment and prevention of allergy-related conditions.

NEWS

19th Jul 2018 Proposed placing and subscription to raise up to £10.6 million
13th Jul 2018 Hardman & Co Research
12th Jul 2018 Trading update
25th Jun 2018 Positive data of Pollinex Quattro Grass vaccine
29th May 2018 Positive data with house-dust mite immunotherapy
21st May 2018 Positive top-line results from Grass Ph II study
14th May 2018 Publication of MCT Adjuvant Data
07th Mar 2018 Hardman Research: Clinical development towards submission
07th Mar 2018 Interim Results for the six months ended 31 December 2017


VIDEO/AUDIO
21st May 2018 Allergy Therapeutics on track for phase III grass pollen trial in 2019
September 2017 5 minute pitch
09th May 2016 Allergy Therapeutics boss excited by PQBirch204 Phase II data
08th Mar 2016 Allergy Therapeutics says double-digit revenue growth is sustainable
18th Feb 2016 Allergy Therapeutics hopes to launch "exciting" grass pollen allergy vaccine in 2019
14th Jan 2016 Allergy Therapeutics boss says the firm is outperforming its competitors

EVENTS
27 11 2018 AGM (tentative)
03 10 2018 Shares Investor Evening (London)
26 09 2018 Preliminary Annual Results 2018 Announcement (tentative)


WEBSITES

13 June 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")

Allergy Therapeutics hosts Satellite Symposium at EAACI

~ World-leading allergists present technological advances and immunotherapy innovations ~

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces today that data was presented in a Satellite Symposium entitled: "Adjuvants in Allergy: elevating efficacy" at the 35th Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) in Vienna, Austria on 12 June 2016, relating to a number of the Company's products and technologies.

Three world-leading experts in the field of allergen immunotherapy and vaccine delivery, Ralph Mösges, Randolph Brehler and Thomas Kündig, presented information on innovation in immunotherapy including Allergy Therapeutics' key product Pollinex Quattro®. Pollinex Quattro®'s specialist technology was discussed, highlighting the marketed product's ability to reduce irritation and systemic reactions. Furthermore, Dr Brehler discussed how the potent depot adjuvant MCT (Micro Crystalline Tyrosine), initiated by the Company as an alternative to aluminium in subcutaneous immunotherapy and used in Pollinex Quattro® as well as certain other of the Company's subcutaneous injected therapies, has an immunomodulating action that augments a shift in the immune reactions responsible for the symptoms of allergic rhinitis.

Data on the future role of Virus-Like-Particles (VLP) in immunotherapy was also presented as a potential new injectable vaccine immunotherapy technology. Allergy Therapeutics recently acquired an exclusive VLP technology licence and is conducting a research project on VLP-based allergy vaccines. The worldwide food allergy market is worth a potential $8bn and, currently, there is no established and safe immunotherapy treatments available for peanut allergy, the first indication the Company intends to address.


Manuel Llobet, Chief Executive Officer, commented: "As a fully integrated specialty pharmaceutical company, we are delighted to be breaking new ground in allergen immunotherapy. Allergy Therapeutics has the potential to transform allergy treatment with an established range of diagnostics and specific short-course aluminium-free immunotherapy vaccines and we are well-placed to deliver the relief from symptoms of allergy that millions of patients need."

Satellite Symposium: Adjuvants in Allergy: elevating efficacy

1) Ultra-short course immunotherapy, Ralph Mösges MD, PhD, MSEE, University of Cologne (Pulmonology, Allergology and Clinical Immunology)

2) Adjuvants in immunotherapy, Randolf Brehler MD, University of Münster (Allergology)

3) Future immunotherapy: virus like particles, Thomas Kündig, University Hospital Zurich (Immunology, Cell Biology and Pharmacology)

http://www.moneyam.com/action/news/showArticle?id=5358789

Shares Spotlight - Manuel Llobet CEO of Allergy Therapeutics (AGY)
Published on Jun 13, 2016

Mark Dunne interviews Manuel Llobet who discusses his companies allergy products.

27 June 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")

Allergy Therapeutics announces findings from mEEC dose range finding study G204

~ Further dose range finding required and US plans progress with goal of being first to market ~

~ Group's European sales accelerate at 19% growth rate ~

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces findings from its exploratory Phase II dose-ranging study (G204) for the US GrassMATAMPL clinical development program and informs that the results did not determine a recommended dose for the Phase III trial. A further dose range finding study will be implemented prior to proceeding into the planned pivotal Phase III study. GrassMATAMPL is an ultra-short course subcutaneous allergen specific immunotherapy ("SCIT") administered prior to the grass pollen season.

Based on the successful dose response data identified in the Phase II G203 study for the same US GrassMATAMPL programme, the G204 trial was designed to explore higher dose regimens using the novel technology of the mEEC (mobile environmental exposure chamber) and optimise the recommended dose before starting the pivotal Phase III trial (G306) to be performed in the US.

In contrast to the G203 study, the dose range finding data with the mEEC did not allow the Company to recommend an optimised dose regime to take into Phase III studies for the US. Consequently, Allergy Therapeutics will undertake a further dose-ranging study employing the same successful European dose-finding trial design with a fixed Conjunctival Provocation Test (CPT) which provided robust results for the optimisation of the Company's marketed subcutaneous birch pollen product, Pollinex® Quattro Birch (PQBirch).

The next dose range finding study is planned to start in 2017. Allergy Therapeutics will await the outcome of an End of Phase II meeting with the FDA, scheduled later in 2016, before progressing into Phase III.

Commenting on the announcement, Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, said: "Defining the optimal dose is part of late-stage product development and we will revisit dose evaluation as we recently successfully did with our PQ Birch product, using two separate and complimentary dose-ranging studies. Additionally, the new findings of our Phase II EEC study will need to be discussed with FDA before deciding on the recommended dose for the following Phase III registration trial. While still being determined to become the first company to introduce SCIT to the US, a deferred entry time into the market is now anticipated.

"In Europe, our market penetration continues to accelerate, outperforming the market with 19% year-to-date revenue growth*, an increase from the 12% revenue growth* we had achieved in December 2015.

"Elsewhere in the pipeline, we successfully completed a Phase IIb dose finding study for Pollinex Quattro Birch in Germany and Austria earlier this year; we've completed the exploratory dose finding study in the US; set up the protocols for the Acarovac Quattro programme in Spain; and we have initiated the proof-of-concept plan for the VLP Peanut allergy vaccine in Switzerland.

"We are progressing with our plans and are very excited by the prospects of building a leading subcutaneous company in Europe as well as in international markets."

*revenue growth is at constant currency and is supported by the Immunal acquisition.

http://www.moneyam.com/action/news/showArticle?id=5366973

8 July 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")

Allergy Therapeutics announces publication of 1-year follow up results of its mite allergoid immunotherapy Acarovac Plus™

~ Significant decreases in symptom scores reported with Acarovac Plus ~

~ Product treatment was proven to be well tolerated and safe ~

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces the publication of a 1-year follow-up study of patients using Acarovac Plus™, its unique, microcrystalline tyrosine-adsorbed, house dust mite-allergoid subcutaneous immunotherapy in the peer-review journal Immunotherapy.

A previous study in 2014, led by Dr Albert Roger, Director of the Allergy Unit at Universitari Hospital Trias I Pujol, Badalona, Spain, assessed the tolerability and safety of Acarovac Plus™ in patients with respiratory allergy to Dermatophagoides pteronyssinus under conditions of normal clinical practice. This 1-year follow-up investigation, with the existing patient pool and testing regimen, assessed effectiveness using a nasal provocation test and measurement of immunological markers that are indicative of immunotherapy success.

A statistically significant reduction in symptom scores was observed at both follow-up visits (four weeks and one year), with >50% reduction in symptom scores recorded after one year. Moreover, significant improvements in immunological markers were noted at the follow-up visits. Patients reported statistically significant improvements in satisfaction scores after one year in relation to overall effectiveness and convenience of the treatment.

2016 has seen a significant increase in sales of Acarovac Plus™ to over EUR 1 million in key markets Spain and Portugal, compared to 2015. Sales of house dust mite immunotherapy are expected to increase rapidly over the coming years with over 20% of the population in Europe experiencing an allergic reaction to house dust mites. Therefore, Allergy Therapeutics is continuing to develop Acarovac Quattro™, an ultra-short course therapy utilising the adjuvant monophosphoryl lipid A (MPL), which is used in the Company's successful Pollinex Quattro product range currently in late stage development in Europe and the US to complement Acarovac Plus™.

Commenting on the publication, Dr Albert Roger, principal investigator for the study, said: "The successful clinical results in the 1-year follow-up study clearly demonstrate the effective treatment of house dust mite allergy by Acarovac Plus™. We also observed significant decreases in symptom scores and improvement in nasal sensitivity immediately after the up dosing phase of one month and a high rate of patient satisfaction early in treatment."

Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, said: "This data further reinforces the benefits of Acarovac Plus™ in the perennial allergy vaccine market. Using maintenance injections six weeks apart, Acarovac Plus™ has been shown to decrease the symptoms of house dust mite allergy one year after treatment. This dosing regime has the potential to improve the adherence and compliance that is essential for a successful treatment. Acarovac Plus™ bolsters our portfolio of allergy immunotherapy products on the market in Europe and we look forward to continued good growth."

http://www.moneyam.com/action/news/showArticle?id=5376022

Allergy Therapeutics sees "statistically significant" improvement one year on
07:40 08 Jul 2016

“Acarovac Plus bolsters our portfolio of allergy immunotherapy products on the market in Europe and we look forward to continued good growth.”



Allergy Therapeutics plc (LON:AGY) reported statistically significant reduction in symptoms in patient studies to test the efficacy of its dust mite allergy immunotherapy treatment.

The allergy vaccines group published its one-year follow-up study of patients using Acarovac Plus, its flagship dust mite allergy vaccine.

A statistically significant reduction in symptom scores was observed at both follow-up visits (four weeks and one year), with a reduction of up to 50% in symptom scores recorded after one year.

Significant improvements in immunological markers were noted at the follow-up visits, said the group.

With over 20% of Europeans allergic to dust mites, sales of house dust mite immunotherapy are expected to increase rapidly over the coming years.

“Acarovac Plus bolsters our portfolio of allergy immunotherapy products on the market in Europe and we look forward to continued good growth,” said chief executive Manuel Llobet.

Josh Allsopp

13 July 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")

Trading Update

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today provides a trading update for the year ended 30 June 2016 ahead of its Preliminary Results to be announced in September 2016.

Financials

Reported revenues are expected to be £48.5m (2015: £43.2m), slightly ahead of current market expectations. This represents a growth of 12%* despite the negative impact from the weakening Euro during most of the year. At constant currency, this represents a growth of 19%* for the year. This solid growth has been against a flat market backdrop and has allowed the Company to increase its market share two percentage points from 10% to 12% on average across its key European markets. The main contributions in terms of market share gains for the Company have come from Germany, Austria, Spain and the UK.

Product

Allergy Therapeutics' market penetration is consistent across the product portfolio, particularly from Pollinex Quattro, Oralvac (which has benefited from a competitor situation) and our newer products entering the market including Acarovac and Synbiotics.

The Company expects strong revenue growth to continue for several years and aims to achieve a leading European market position in the allergoid subcutaneous immunotherapy product (SCIT) market before 2020.

Pipeline

In Europe, the development program for PQ Birch is on track and the Pivotal Phase III study is planned to start in H1 2017. For the US, the Company will perform another dose ranging study for PQ Grass in order to ensure that the best dose is chosen for the final Phase III study. Acarovac Quattro development is on track and initiation of Phase I studies is expected to start in H2 2016. Finally, the proof of concept study for the novel vaccine, Polyvac Peanut, is progressing according to plan.

Commenting on the positive trading update, Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, said:

Our strong sales growth of 19%* at constant rates and further gain in market share of two points to 12% shows that our ambition to build a world-leading portfolio of aluminium-free, patient-friendly vaccines is gaining increased traction. We continue to invest in our business and remain on course to become the leading company in the subcutaneous segment. We are also very excited about the commercial opportunities in our current broad portfolio."

*The growth figures include 3% which relates to the acquisition of the Alerpharma business in June 2015.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

http://www.moneyam.com/action/news/showArticle?id=5378575

Allergy Therapeutics' revenues top forecasts
11:25 13 Jul 2016

Updating investors, the company said turnover will be around £48.5mln, representing a rise of 12%, or 19% once the figure is adjusted for currency movements.



Allergy Therapeutics plc (LON:AGY) said revenues for the year ended June were slightly ahead of market expectations.

Updating investors, the company said turnover will be around £48.5mln, representing a rise of 12%, or 19% once the figure is adjusted for currency movements.

Against a “flat backdrop”, the business, which specialises in allergy vaccines, has grown its market share by two percentage points to 12%.

Gains were made in Germany, Austria, Spain and the UK where demand for products such as Pollinex Quattro, Oralvac and newer lines, such as Acarovac and Synbiotics, remains buoyant.

IN DEPTH: Getting under the skin of Allergy Therapeutics

AT A GLANCE: All facts and figures

“The company expects strong revenue growth to continue for several years,” Allergy added.

Turning to the pipeline, it said a phase III study for its PQ Birch product should get underway in the first half of next year, while in the US the company is in the process of deciding the optimum dose for its phase III trial of PQ Grass.

“We continue to invest in our business and remain on course to become the leading company in the subcutaneous segment,” said chief executive Manuel Llobet.

“We are also very excited about the commercial opportunities in our current broad portfolio."

Broker reckons the stock could more than double in value

The shares rose 4% to 19.77p, valuing the business at £122mln. The broker Panmure Gordon reckons the stock is worth 53p.

“With our investment thesis fundamentally unchanged despite the speed bump of the US dose ranging study we view the share price reaction offers investors an excellent opportunity,” said analyst Dr Mike Mitchell.

About the company

Allergy Therapeutics has an 80-year history and is no “jam tomorrow” drug development company.

It has a profitable core business and, as the name suggests, a number of ground-breaking allergy vaccines that trade under various brand names. Its most commonly prescribed vaccines are used to treat pollen-related allergies, particularly allergies to grasses and trees.

It has has a strong presence in Europe with established operations in Germany, Italy, Spain, Austria, Switzerland, the Netherlands and the United Kingdom, while in other markets it often makes its products available through distribution partners.

Its Pollinex Quattro vaccine for the treatment of seasonal allergic rhinitis (hay fever) from grass, tree or ragweed pollen allergy is already established in Europe, and the company wants to replicate that in the US, where it will enjoy first mover advantage in a market potentially worth $2bn.

---ADDS BROKER COMMENT & SHARE PRICE---

Ian Lyall

Profit from the market's Allergy reaction
By Megan Boxall,
21 July 2016

Using immunotherapy - stimulating the immune system - to treat allergies is rapidly gaining traction. As a scientific discipline it's not particularly new, but for a long time it has been difficult to safely and effectively revamp the body's immune system by injecting a small dose of an allergen. However, recent improvements in science, alongside increased investor interest, has carved a path for a multibillion-dollar global market and Aim-traded Allergy Therapeutics (AGY) is in an excellent position to take a slice of this.

***The content of this section is only available to Investors Chronicle online subscribers.***

This symposium was highlighted in Post 25 and is now featured on the European Medical Journal website for download:

Disclosure: Prof Matthias Kramer is an employee of Allergy Therapeutics UK Ltd


Adjuvants in Allergy: Elevating Efficacy
August 2, 2016

Meeting Summary

This symposium provided an overview of the current and future technologies and treatments used in the field of allergen immunotherapy (AIT). Prof Ralph Mösges explored the concept of pre-seasonal immunotherapy in overcoming the problem of recurrent allergy, focussing on the use of Pollinex® Quattro versus the use of symptomatic treatment according to current guidelines. The use and mechanisms of adjuvants was explored by Prof Randolf Brehler, who discussed the use of adjuvants in AIT including delivery systems, immunopotentiators, and targeted delivery systems to facilitate optimum immune responses with the potential of a lower injection burden and increased efficacy of treatment. Prof Thomas Kündig concluded the symposium with an overview of the future of AIT and the use of virus-like particles (VLP) in harnessing the innate immune system response to protect against allergens.



and link to the actual download:

http://emjreviews.com/wp-content/uploads/Adjuvants-in-Allergy-Elevating-Efficacy.pdf

Who Should Attend?Date:

Tuesday 27th September 2016

Venue:

Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR

Event Timings:Sponsored by:

Was just copying that over, cheers Bullshare

saved you :-0)

Allergy Therapeutics Plc to present at the Shares Investor Evening in London on 27th September 2016

31 August 2016 | 15:29pm

StockMarketWire.com - Manuel Llobet, CEO and Nick Wykeman, FD of Allergy Therapeutics (AGY) (LSE:AGY) will be giving a briefing at the Shares Investor Evening on 27th September 2016. It will take place in London at an investor evening being organised by Shares magazine; the event is supported by AJ Bell Youinvest.

Allergy Therapeutics provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with a special focus on allergy vaccination (also known as specific immunotherapy or desensitisation therapy). Allergy vaccination is a successful treatment that deals with the underlying cause of allergies and not just the symptoms! Allergy Therapeutics has a long-term commitment to the development of innovative therapies for allergy treatment and allergy prevention.

The Shares event offers a unique opportunity to hear about the latest plans and strategy from the Directors of UK listed companies and Fund Managers, attendees can personally put forward questions to the presenters. The event will take place at the Novotel Tower Bridge, 10 Pepys Street, London EC3N 2NR. Registration begins at 17:15 and presentations at 17.45, followed by a drinks reception where attendees can mingle with the speakers and fellow investors.

http://www.stockmarketwire.com/article/5406664/Allergy-Therapeutics-Plc-to-present-at-the-Shares-Investor-Evening-in-London-on-27th-September-2016.html

Allergy Therapeutics schedules FY results

Allergy Therapeutics will issue its preliminary results for the 12-month period ended 30 June on 26 September

http://www.moneyam.com/action/news/showArticle?id=5408944

Prelim.Results 26th September then on 27th September AGY will be giving a briefing at the Shares Investor Evening.......

26 September 2016
Allergy Therapeutics plc

Preliminary report for the year ended 30 June 2016


- Significant progress made towards becoming a global provider of allergy solutions -

Allergy Therapeutics plc, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces preliminary results for the year ended 30 June 2016.

Highlights

· 19% increase in revenue at constant currency to £51.5m (2015: £43.2m)*

· 12% increase in revenue to £48.5m (2015: £43.2m)

· Increased market share in our main European markets to 12% (2015: 10%)

· Core business (excluding R&D) shows 11% increase in Operating Profit to £4.3m (2015: £3.8m)

· Ramp up on R&D investment with £16.2m (2015: £3.1m) spent, reflecting investment in PQ registration and pipeline

· Achieved primary endpoint for PQ Birch Phase II Study in Europe and selected dose to be used in Phase III, starting in 2017

· Inconclusive results of Phase II dosing study in the US for Pollinex Quattro Grass

· Successfully raised £11.5m (gross) to fund new product development and organic and inorganic growth opportunities

· Acarovac PlusTM one-year study showed statistically significant improvement for patients

· Acquisition of Virus Like Particle technology licence for the development of a potential new injectable vaccine immunotherapy treatment for allergy sufferers with peanut as lead project

· Strong cash balance of £23.4m at year end (2015: £21.2m)

Manuel Llobet, Chief Executive Officer, commented: "This year has seen many events in the allergy market. I would like to highlight Allergy Therapeutics' revenue growth, now accounting for 12% of the share in our competitive market, and progressing well towards our long-term strategic plans with developments across all areas of the business.

Our excellent products and outstanding team have delivered success in product development and marketing and, despite the requirement for our additional range-finding study, we look forward to capitalising on opportunities to continue growing into new markets and delivering patient-friendly, market-leading treatments, to help patients across the allergy spectrum.

We are a thriving, visionary company, led by a self-driven team, totally committed to transforming allergy treatments. We are passionate about what we do and we are convinced that the best is yet to come."

http://otp.investis.com/clients/uk/allergy_therapeutics/rns/regulatory-story.aspx?cid=1045&newsid=789353

Hardman & Co Report

http://hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics-documents/26.09.16-excellent-performance-drives-market-share-gains.pdf

MAM managing to report another news item :-)

26 September 2016
 
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
 
Director/PDMR Shareholding
 
Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that on 26 September 2016, the Board of Allergy Therapeutics was informed that today Manuel Llobet, Chief Executive Officer, purchased 100,000 ordinary shares of 0.10p in the Company ("Ordinary Shares") at a price of 18.0 pence per Ordinary Share.  Mr Llobet's beneficial holding now stands at 3,275,000 Ordinary Shares, which represents 0.56% of the issued share capital of the Company to which voting rights are attached.
 
- ENDS -

http://www.moneyam.com/action/news/showArticle?id=5421000

Reminder of tonight's event:

Allergy Therapeutics Plc to present at the Shares Investor Evening in London on 27th September 2016

31 August 2016 | 15:29pm

StockMarketWire.com - Manuel Llobet, CEO and Nick Wykeman, FD of Allergy Therapeutics (AGY) (LSE:AGY) will be giving a briefing at the Shares Investor Evening on 27th September 2016. It will take place in London at an investor evening being organised by Shares magazine; the event is supported by AJ Bell Youinvest.

Allergy Therapeutics provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with a special focus on allergy vaccination (also known as specific immunotherapy or desensitisation therapy). Allergy vaccination is a successful treatment that deals with the underlying cause of allergies and not just the symptoms! Allergy Therapeutics has a long-term commitment to the development of innovative therapies for allergy treatment and allergy prevention.

The Shares event offers a unique opportunity to hear about the latest plans and strategy from the Directors of UK listed companies and Fund Managers, attendees can personally put forward questions to the presenters. The event will take place at the Novotel Tower Bridge, 10 Pepys Street, London EC3N 2NR. Registration begins at 17:15 and presentations at 17.45, followed by a drinks reception where attendees can mingle with the speakers and fellow investors.

http://www.stockmarketwire.com/article/5406664/Allergy-Therapeutics-Plc-to-present-at-the-Shares-Investor-Evening-in-London-on-27th-September-2016.html

28 September 2016
Allergy Therapeutics plc

Director/PDMR Shareholding

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that the Board of Allergy Therapeutics was informed that on 27 September 2016 Nicolas Wykeman, Finance Director, purchased 150,000 ordinary shares of 0.10p in the Company ("Ordinary Shares") at a price of 17.75 pence per Ordinary Share. Mr Wykeman's total beneficial holding amounts to 150,000 Ordinary Shares, which represents 0.04% of the issued share capital of the Company to which voting rights are attached.

http://uk.advfn.com/stock-market/london/allergy-therapeutics-AGY/share-news/Allergy-Therapeutics-PLC-Director-PDMR-Shareholdin/72538369